RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors

Glen Rock, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the appointment of Dr. Dariusz Nasiek MD, MBA to its board of directors. Dr. Nasiek is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management. Dr. Nasiek is board certified by the American Board of Anesthesiology, the American Board of Pain Medicine and the American Board of Interventional Pain Physicians. Dr. Nasiek is also a Life Member of the American Society of Interventional Pain Physicians and a Member of the International Spine Intervention Society. He has been a practicing physician for the last 35 years. Since 2006, he has been the Managing Partner of Allied Neurology & Interventional Pain Practice, and since 2008, he has served as the Director of Anesthesiology at Hackensack Surgery Center. Dr. Nasiek is a leader specializing in non-surgical options for the treatment of spinal and non-spinal pain and is a pioneer in the use of innovative techniques in the cervical, thoracic and lumbar spine. His forward-looking approaches to pain management, regenerative medicine and tissue healing are described in the new 2nd Edition of his book entitled, “PRP, Platelet Rich Plasma: A New Paradigm in Regenerative Medicine.”

“It is a pleasure to welcome Dr. Nasiek as a director on our board. He brings considerable value not only his status as an outside director, but the perspective that he provides because of his considerable clinical experience in the areas in which RespireRx is developing its compounds: treatment of respiratory disorders and spinal injury with our AMPAkine platform and the development of our GABAkines for use as non-narcotic analgesics and for treatment resistant epilepsy,” said Arnold Lippa, Executive Chairman of the Board, Interim Chief Executive Officer, Interim President and Chief Scientific Officer.

“I am pleased to join the RespireRx board of directors and look forward to contributing significantly based upon my extensive direct patient experience with most opportunities being developed by the company and my broader medical experience as well as my general medical and life science intellectual curiosity. I am excited about the science, the clinical development strategies and the potential breakthroughs for patient care,” said Dr. Nasiek.